ProMIS Neurosciences announced that its Alzheimer's drug candidate PMN310 demonstrated a dose-dependent reduction of toxic amyloid-beta oligomers in cerebrospinal fluid of healthy volunteers, marking one of the first quantitative proofs of target engagement in humans. This selective targeting of oligomers, believed to drive Alzheimer's disease, could improve treatment safety and efficacy by avoiding plaque-related side effects. The company plans to present six-month interim data from its ongoing Phase 1b trial soon, aiming to further validate PMN310's clinical benefits in Alzheimer's patients.
ESET researchers discovered 11 outdated UEFI shim bootloaders signed by Microsoft that can bypass UEFI Secure Boot on most UEFI-based systems, allowing attackers to run malicious code during boot. These vulnerabilities affect any system trusting Micr...
Crunchafi has introduced a new software solution to support UK and Ireland firms with the revised FRS 102 Section 20 lease accounting standard effective from January 2026. This update requires many leases to be recognized on balance sheets, increasin...
In June 2026, US supply chains expanded at their fastest rate since March 2022, with the Logistics Managers’ Index rising to 71.1 from 69.5 in May. This growth was driven by resilient consumer spending, prompting retailers to increase inventory ahead...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed client trades involving 58,445 ordinary shares on July 13, 2026. The shares were both bought and sold at prices ranging between £8.925 and £9.09 per share. There were n...
The global industrial semiconductor market, valued at $98.35 billion in 2025, is projected to grow to $329.73 billion by 2035, with a CAGR of 12.86%. Growth is fueled by increasing adoption of AI-powered industrial automation, electric vehicles, smar...
